In short Read article

Acetylsalicylic acid for patients with diabetes but without cardiovasc


Patients with diabetes are at increased risk of cardiovascular disease. One plausible option to prevent these cardiovascular diseases could be the use of acetylsalicylic acid as a primary prevention. Recent research has found evidence that the efficacy of this treatment is minimal, whereas the risk of haemorrhage is not negligible. In line with the Dutch guidelines, these findings do not support the use of acetylsalicylic acid in the primary prevention of cardiovascular diseases among patients with diabetes.

  • The study discussed here reported that the preventive use of acetylsalicylic acid did slightly reduce the number of first-time cardiovascular events among patients with diabetes. In order to prevent one cardiovascular event, 91 patients need to be treated with acetylsalicylic acid for about 7 years.
  • The slight reduction in the number of cardiovascular events that was found disappears when TIAs (which are clinically less serious) are excluded.
  • The Dutch guidelines do no recommend the preventive use of acetylsalicylic acid for patients with diabetes who do not suffer from cardiovascular disease. The study discussed here offers no arguments to adjust these guidelines.
  • The use of acetylsalicylic acid by relatively healthy patients with diabetes should not be recommended. Its benefits are minor and are offset by an increased risk of serious haemorrhage. 

  1. Bowman L, Mafham M, Stevens W, Haynes R, Aung T, Chen F, et al. ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes. Am Heart J. 2018;198:135-44.
  2. McNeil JJ, Woods RL, Nelson MR, Reid CM, Kirpach B, Wolfe R, et al. Effect of Aspirin on Disability-free Survival in the Healthy Elderly. N Engl J Med. 2018;379(16):1499-508.
  3. McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, et al. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. N Engl J Med. 2018;379(16):1509-18.
  4. McNeil JJ, Nelson MR, Woods RL, Lockery JE, Wolfe R, Reid CM, et al. Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. N Engl J Med. 2018;379(16):1519-28.
  5. Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036-46.
  6. Ridker PM. Should Aspirin Be Used for Primary Prevention in the Post-Statin Era? N Engl J Med. 2018;379(16):1572-4.
  7. Kerst AJFA. Acetylsalicylzuur voor gezonde ouderen? Gebu. 2019;53(2):22-4.
  8. van Deventer K, Janssens HJEM. Klinische relevantie van onderzoeksuitkomsten. Wat schiet de patiënt ermee op? Gebu. 2019;53(1):1-11.
  9. Vereniging NI. Diabetes mellitus type 2 bij ouderen 2018 [Available from: https://richtlijnendatabase.nl/richtlijn/diabetes_mellitus_type_2_bij_ouderen/startpagina_-_dm_type_2_bij_ouderen.html.
  10. Genootschap NH. NHG-Standaard Diabetes mellitus type 2 (Vierde (partiële) herziening) 2018 [Available from: https://www.nhg.org/?q=standaarden/volledig/nhg-standaard-diabetes-mellitus-type-2.

Authors

  • mw drs M.A.E. Nieuwhof